Entropy Analysis and Complex Patient-ventilator Interactions During Mechanical Ventilation (ENTROPY-ICU)

July 3, 2020 updated by: Candelaria de Haro, Corporacion Parc Tauli

Entropy Analysis and Complex Patient-ventilator Interactions During Invasive Mechanical Ventilation at Intensive Care Unit Setting

Complex patterns of patient-ventilator interactions could be miscalculated by visual observation of mechanical ventilator screens or current algorithms based on physiologic waveforms to detect patient-ventilator asynchronies. Therefore, we aim to characterize, validate and study the clinical distribution and implications of an automated and personalized non-invasive tool based on Entropy to detect Complex Patient-Ventilator Interactions (CP-VI) during mechanical ventilation, defined as breathing pattern change and/or clusters of asynchronies, over the signals of airway pressure (Paw) and airway flow (Flow).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Methods

  1. Defining complex patient ventilator interactions The Investigators defined "Complex Patient-Ventilator Interactions" (CP-VI) as the presence alone or in combination of a change in the respiratory rate of more than 50%, and/or the occurrence of any kind of asynchronies
  2. Data acquisition and data analysis Paw and Flow signals will continuously recorded throughout patient's stay in the Intensive Care Unit (UCI) using BetterCare® system (Better Care®, Barcelona, Spain). BetterCare uses drivers specifically designed to interact with the output signal of mechanical ventilators and bedside monitors rather than directly with patients. Recorded signals are synchronized and stored for further analysis. MATLAB (The MathWorks, Inc., vR2018b, Natick, MA, USA) will be used to perform the signal processing, data analysis and visual assessment.
  3. Study Population The Investigators will obtain data from an prospectively constructed database from a connectivity platform (Better Care®) to interoperate signals from different ventilators and monitors and subsequently compute algorithms to diagnose patient-ventilator asynchronies (ClinicalTrial.gov, NCT03451461). All of those patients corresponding to a self-extubation event previously recorded will be recruited for the characterization and validation process, in order to guarantee at patient-ventilator interactions and episodes when they fight the ventilator. Also, patients in whom an spontaneous breathing trial previous to an attempt to librate him/her from the ventilator will be recruited in order to obtain signals of Paw and Flow. Clinical and demographic data will obtained from the medical chart. The institutional review board approved the protocol and waived informed consent because the study was non-interventional, posed no added risk to patients, and did not interfere with usual care.
  4. Visual validation of CP-VI Three researchers will visually review the Flow and Paw recordings of events. The segments duration will selected based on previous studies where asynchronous clusters are evaluated. The dataset will be previously selected by an expert in mechanical ventilation ensuring balance by ventilation modes (grouped by Pressure Support Ventilation (PSV) and Assist-Control Ventilation modes) and equal distribution of CP-VI presence or absence. The controlled modes included volume assist-control ventilation (VACV) and pressure assist-control ventilation (PACV). Flow and Paw tracings will be randomly ordered in MATLAB prior to visual analysis to ensure blinding of the scorers. Scorers will be provided with written description of CP-VI characteristics before visual analysis, as a reference. On base of CP-VI definition previously described, each researcher will score for the presence or absence of CP-VI events, without time limitation. The visual assessment will considered as the gold standard.
  5. Entropy Entropy is a non-linear measure that allows assessing the randomness of a series of data. Entropy calculation requires three parameters: the embedding dimension, m (a positive integer); the tolerance value or similarity criterion, r (a positive real number); and the total length, N, of the analysed series.
  6. Automatic CP-VI detection An automated algorithm for CP-VI detection based on Entropy tool will be implemented.
  7. Statistical analysis Fleiss's kappa coefficient will be used as reliability of agreement among raters for visual assessment. The automated algorithm for CP-VI detection will be applied over the entropy series derived from the same Flow and Paw. The performance of the automated algorithm will be evaluated on base of sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV and NPV, respectively), accuracy (ACC) and Matthews correlation coefficient (MCC).
  8. Selection of m, r and N In entropy studies, an important step is to determine the optimal settings to robust extract the randomness of a series of data. Therefore, an optimization procedure of m, r and N will performed to properly estimate CP-VI.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
107

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Barcelona
      • Sabadell, Barcelona, Spain, 08208
        • Hospital Universitari Parc Tauli

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults patients admitted to the Intensive Care Unit without exclusion criteria and who develop a self-extuation episode or a spontaneous breathing trial will be recruited.

Description

Inclusion Criteria:

  • Admission to a ICU bed equipped with BetterCare software and intubated fo mechanical ventilation expected to last more than 24hs
  • patients who develops a self-extubation episode or a spontaneous breathing trial.

Exclusion Criteria:

  • <18 years
  • <48hs of recorded data
  • moribund state
  • admission for organ donation
  • chest tubes with suspected bronchopleural fistula
  • accidental extubation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
self-extubation
patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
Other: processing signals of airway pressure and airway flow to calculate entropy
processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
spontaneous breathing trial
patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
Other: processing signals of airway pressure and airway flow to calculate entropy
processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
validation of entropy to detect complex patient-ventilator interactions
Time Frame: 3 months
validation process of a the novel tool of entropy to detect properly complex patient-ventilator interactions compared to a group of experts physicians in mechanical ventilation
3 months
successful extubation (remaining free of mechanical ventilation 72 hours after extubation) in those patients with complex patient-ventilator interactions
Time Frame: 6 month
analizing the clinical course during the first week after extubation obtaining data from the medical chart and quantifier the distribution over time of complex patient-ventilator interactions detected by entropy.
6 month

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Rate of reintubation
Time Frame: 6 months
quantifier the distribution over time of complex patient ventilator interactions detected by entropy in those patients who requiere reintubation in both cohorts
6 months
Intensive care unit and hospital length of stay
Time Frame: 6 months
quantifier the distribution over time of complex patient ventilator interactions detected by entropy in all patients included and in both cohorts and study the duration of their hospitalization
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Corporacion Parc Tauli

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Lluis Blanch, M.D., Ph.D., Critical Care Center, Hospital Universitari Parc Tauli. Institut d'Investigació i Innovació Parc Taulí.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2019

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2019

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 14, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 14, 2019

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 16, 2019

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 7, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Tauli entropy-ICU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The protocol as well as the study outcomes does not stipulate ta IPD should be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings